AEGLIX vulnerability intelligence
CVE-2026-5781
HIGH · CVSS 8.5 · Analyzed
Published: 2026-04-28 · Updated: 2026-10-26 · Source: NVD
Stored catalog record
Source record retrieved 2026-10-28T10:19:45.635768+00:00. Scheduled imports handle updates; this page does not assert that the provider was queried just now.
Vulnerability overview
An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modification privileges to escalate their privileges by sending an HTTP request with a manipulated 'identifier' field. Successful exploitation of this vulnerability could allow an authenticated user to obtain administrator privileges. It is not possible to escalate privileges through the graphical user interface.
Patch review priority
Assess exposure and vendor guidance
- No higher-priority signal is available in the current stored evidence.
FIRST EPSS: 0.23% · percentile 14.0 · score date 2026-10-27.
EPSS estimates probability of exploitation in the next 30 days. It does not measure your exposure or prove exploitation. The elevated threshold is 10%; CISA KEV takes precedence. About FIRST EPSS ↗
Severity and scoring
- CVSS score
- 8.5 · HIGH
- CVSS version
- 4.0
- CVSS vector
- CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
- Weaknesses
- CWE-285
CVSS measures technical severity; it does not establish whether this vulnerability is being exploited in your environment.
Known exploitation and remediation
Not listed in the CISA catalog retrieved for this record. This does not establish that exploitation has not occurred.
Verify affected versions and patch availability in the vendor advisory before making changes.
Affected products and versions
cpe:2.3:a:agilonhealth:minerva:3.6.0:*:*:*:*:*:*:*
These are NVD CPE applicability entries. Some products depend on configuration conditions; consult the official record to confirm applicability.